[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gulhane Training and Research Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":162},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,76,106,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644817","relationship-of-peripheral-inflammatory-and-neuroprotective-biomarkers-with-response-to-intermittent-theta-burst-stimulation-in-treatment-resistant-depression-100644817",false,"NCT07673913","Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression","Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression","TRD-BIOTMS","Inclusion Criteria:\n\nTreatment-Resistant Depression Group:\n\nAge between 18 and 55 years. Male or female participants. Diagnosis of Major Depressive Disorder according to DSM-5-TR criteria. Inadequate response to at least two antidepressant treatments administered at adequate doses and durations.\n\nEligible for transcranial magnetic stimulation (TMS) treatment. Able and willing to provide written informed consent. Able to complete neuropsychological assessments. Able to attend study visits and complete the treatment protocol.\n\nHealthy Control Group:\n\nAge between 18 and 55 years. Male or female participants. No current DSM-5-TR psychiatric disorder. Able and willing to provide written informed consent. Able to complete neuropsychological assessments.\n\nExclusion Criteria:\n\nSchizophrenia, bipolar disorder, organic mental disorders, or other major psychiatric disorders.\n\nHistory of epilepsy, brain tumor, severe head trauma, or significant neurological disease.\n\nAny contraindication to TMS. Presence of intracranial metal implants, cardiac pacemakers, cochlear implants, or other incompatible implanted devices.\n\nActive infection. Autoimmune disease or chronic inflammatory disease. Electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation within the previous 5 years.\n\nPrevious intravenous or intranasal ketamine treatment. Pregnancy or breastfeeding. Active alcohol or substance use disorder. Inability to comply with study procedures. Inability to tolerate the iTBS protocol. Withdrawal of informed consent at any stage of the study.",true,"ALL","18 Years","55 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","Treatment-resistant depression (TRD) is a major clinical challenge affecting a substantial proportion of patients with major depressive disorder who do not adequately respond to conventional antidepressant treatments. Intermittent theta burst stimulation (iTBS), a non-invasive neuromodulation technique targeting the left dorsolateral prefrontal cortex, has emerged as an effective treatment option for these patients. However, the biological mechanisms underlying treatment response remain poorly understood.\n\nThis single-center, prospective, investigator-initiated clinical study aims to investigate the effects of iTBS on clinical symptoms, executive functions, and peripheral inflammatory and neuroprotective biomarkers in patients with treatment-resistant depression.\n\nFifty patients with treatment-resistant depression and fifty healthy control participants will be enrolled. Patients will receive active iTBS treatment for four weeks (20 sessions), while healthy controls will undergo baseline clinical, cognitive, and biological assessments without receiving any intervention.\n\nClinical outcomes will be evaluated using the 17-item Hamilton Depression Rating Scale (HAM-D-17), Patient Health Questionnaire-9 (PHQ-9), Clinical Global Impression (CGI), and Insomnia Severity Index (ISI). Executive functions will be assessed using the Wisconsin Card Sorting Test, Trail Making Test A and B, and verbal fluency tests.\n\nPeripheral blood samples will be collected before and after treatment to measure inflammatory, neuroplasticity, and neuroprotective biomarkers, including IL-1β, IL-6, IL-10, TNF-α, high-sensitivity C-reactive protein (hs-CRP), brain-derived neurotrophic factor (BDNF), apolipoprotein D (APOD), serum amyloid A1 (SAA1), and serum amyloid A2 (SAA2). Gene expression analyses will also be performed using quantitative polymerase chain reaction (qPCR).\n\nThe study aims to identify biological mechanisms associated with iTBS treatment response and to explore potential biomarkers that may predict clinical improvement in patients with treatment-resistant depression. The findings may contribute to the development of personalized neuromodulation strategies and biomarker-guided treatment approaches for depression.",[29,30],"Treatment-resistant Depression (TRD)","Major Depression",[32,33,34,35,36],"Treatment-Resistant Depression","Transcranial Magnetic Stimulation","Biomarkers","Personalized Psychiatry","Neuromodulation","NOT_YET_RECRUITING","2026-06-23",{"date":40,"type":41},"2026-06-29","ACTUAL",{"date":43,"type":23},"2026-09-01",{"date":45,"type":23},"2027-09-01",{"name":47,"class":48},"Gulhane Training and Research Hospital","OTHER_GOV",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100574880","the-role-of-furosemide-stress-test-in-the-intensive-care-clinic-100574880","NCT06765031","The Role of Furosemide Stress Test in the Intensive Care Clinic","The Role of Furosemide Stress Test in Predicting Acute Kidney Injury Progression and Need for Renal Replacement Therapy in Patients Followed in the Intensive Care Clinic","Inclusion Criteria:\n\n1. Those who meet KDIGO AKI stage 1 and stage 2 criteria in the first 24 hours\n2. Those with sufficient fluid volume (CVP≥6 cmH20)\n3. Female and male patients over the age of 18 will be included in the study\n\nExclusion Criteria:\n\n1. Pregnant patients\n2. Hospitalization due to intoxication\n3. Liver or kidney transplant\n4. Glomerular filtration rate below 30 ml\u002Fmin\u002F1.73m2\n5. Active bleeding\n6. Patients with obstructive uropathy\n7. Patients in need of urgent RRT (K≥6.6 meq\u002FL, pH\\\u003C7.15, pulmonary edema due to fluid overload, uremic complications)\n8. Patients evaluated as KDIGO AKI stage 3\n9. Patients who have received RRT in the last 30 days\n10. Patients with CKD diagnosis\n11. Patients with pulmonary embolism\n12. Hypoalbuminemia≥2.5 g\u002Fdl,\n13. Patients receiving cephalosporin treatment will be excluded from the sample.",{"count":58,"type":23},140,[26],"AKI causes high mortality and morbidity, especially in critically ill patients, and prolongs the patient's stay in the intensive care unit. Due to the high morbidity and mortality associated with AKI, many researchers are studying several new biomarkers for earlier detection of AKI, determination of etiologies, and prediction of outcomes. However, the use of these new biomarkers may be limited due to reimbursement issues. In addition to the therapeutic role of furosemide in fluid balance, blood pressure control, and hypercalcemia management, Chawla et al. recommend the furosemide stress test (FST) as a tool to predict AKI progression. Designing a test that predicts the probability of AKI progression will help us make better decisions regarding the optimal timing of RRT initiation. In this study, we aimed to evaluate the feasibility of using the FST test in determining the progression of AKI in patients hospitalized in the intensive care unit and the need for RRT using the noninvasive procedure furosemide stress test.",[62],"Akut Kidney Injury",[64,65,66],"akut kidney injury","furosemide stres test","continuous renal replasman terapy","RECRUITING","2026-01-08",{"date":70,"type":41},"2026-01-12",{"date":72,"type":41},"2024-11-01",{"date":74,"type":23},"2026-03-31",{"name":47,"class":48},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100595970","molecular-signatures-of-tms-response-in-treatment-resistant-depression-100595970","NCT07039370","Molecular Signatures of TMS Response in Treatment-Resistant Depression","The Relationship Between Plasma Metabolomics and Proteomics Profiling and Response to Transcranial Magnetic Stimulation Therapy in Treatment-Resistant Depression","PROMET_TMS","Inclusion Criteria:\n\n* Diagnosis of Major Depressive Disorder (MDD) according to DSM-5-TR criteria.\n* Inadequate clinical response to at least two different antidepressants and\u002For anti-obsessive agents administered at therapeutic doses and durations.\n* Clinical symptoms not better explained by metabolic or organic medical conditions.\n* No epileptic activity detected on routine electroencephalography (EEG) prior to TMS initiation.\n* Routine pre-TMS laboratory tests reveal no abnormalities that may significantly affect treatment response, including:\n* Normal thyroid hormone profile\n* No significant vitamin deficiencies\n* No markedly elevated inflammatory markers\n* No history or current evidence of hearing loss on clinical evaluation; if present, evaluation by an otolaryngologist will be obtained.\n* Age 18 years and older.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Any contraindication to TMS as identified in the standardized pre-TMS risk assessment form.\n* Presence of epileptic focus detected on pre-TMS EEG.\n* History of significant head trauma, loss of consciousness, or intracranial surgery.\n* Presence of metal implants or foreign bodies incompatible with TMS (e.g., aneurysm clips, surgical clamps, metallic fragments).\n* Abnormal thyroid hormone levels in pre-TMS laboratory testing.\n* Significantly elevated inflammation markers (e.g., CRP) in pre-TMS bloodwork.\n* Vitamin deficiencies associated with cognitive impairment (e.g., B12, folate) in pre-TMS labs.\n* Electrolyte imbalances on pre-TMS blood testing.\n* History of psychotic disorder or bipolar I\u002FII disorder.\n* History of substance-induced psychosis or bipolar disorder.\n* Current or past substance use disorder (including alcohol, stimulants, or illicit drugs), unless abstinent from substances (excluding alcohol) for a minimum of 12 months.\n* Voluntary discontinuation of TMS during the treatment course.\n* Any serious adverse event or unexpected clinical condition during treatment that necessitates discontinuation of TMS.","65 Years",{"count":86,"type":23},55,[26],"Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD). This study aims to identify biomarkers that predict TMS treatment response in TRD, provide insights into the neurobiological mechanisms underlying TMS efficacy, and contribute to personalized treatment strategies. By establishing proteomic and metabolomic signatures, this research seeks to enhance clinical decision-making, reduce healthcare costs, and improve patient outcomes in TRD. The findings will align with the precision medicine movement in psychiatry, advancing biomarker-driven therapeutic approaches for treatment-resistant depression.",[90],"Major Depression Disorder",[92,93,94,95,96],"TMS","Metabolomics","Proteomics","Treatment Resistance","Molecular Signuture","2025-06-17",{"date":99,"type":41},"2025-06-26",{"date":101,"type":41},"2025-06-15",{"date":103,"type":23},"2027-06-01",{"name":47,"class":48},2,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":113,"targetDuration":115,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":49},"100592576","the-role-of-renal-resistive-index-ri-in-predicting-acute-kidney-injury-progression-in-intensive-care-clinic-100592576","NCT06995222","The Role of Renal Resistive Index (RI) in Predicting Acute Kidney Injury Progression in Intensive Care Clinic","The Role of Renal Resistive Index (RI) in Predicting Acute Kidney Injury Progression and Need for Renal Replacement Therapy in Patients Followed in the Intensive Care Clinic","Inclusion Criteria:\n\n1. Being over 18 years of age\n2. Having KDIGO stage 1 or stage 2 acute kidney injury within the first 24 hours of admission\n\nExclusion Criteria:\n\n* 1\\. Patients who did not provide a consent form for participation in the study 2. Patients under 18 years of age 3. Pregnant women 4. Patients with postrenal acute kidney injury 5. Patients 24 hours after the diagnosis of acute kidney injury 6. Patients with acute kidney injury in the recovery period 7. Patients who were evaluated as KDIGO ABH stage 3 during hospitalization 8. Patients with a known history of renal artery stenosis 9. Patients with a diagnosis of cardiac arrhythmia 10. Patients with a diagnosis of chronic kidney disease and a glomerular filtration rate below 30 ml\u002Fmin\u002F1.73m2 11. Patients with intra-abdominal pressure above 20 mmHg 12. Patients with a hospitalization period of less than 24 hours",{"count":114,"type":23},120,"28 Days","OBSERVATIONAL","Acute kidney injury(AKI) is defined in the KDIGO guidelines as a ≥0.3 mg\u002FdL (≥26.5 micromol\u002FL) increase in serum creatinine in the previous 48 hours or a ≥1.5-fold increase in serum creatinine from baseline, known or presumed to have occurred in the previous seven days, or a urine volume \\\u003C0.5 mL\u002Fkg\u002Fhour for six hours.\n\nGiven the high morbidity and mortality associated with AKI, many investigators are studying several novel biomarkers to detect AKI progression earlier, identify etiologies and predict outcomes. However, the utilisation of these novel biomarkers may be constrained by reimbursement considerations.\n\nThe renal resistive index (RRI) is a well-established metric for evaluating renal perfusion; however, its application in the context of AKI has been a subject of recent debate. While RRI has been utilised to demonstrate perfusion in acute and chronic renal diseases, particularly in conjunction with ultrasonography, its efficacy remains a subject of scientific discourse. In addition, Boddi reported that RRI is a strong indicator of mortality and a diagnostic marker, especially in patients with persistent AKI.\n\nThe present study aims to evaluate the appropriateness of using the RRI, a non-invasive procedure, to determine the progression of AKI stages and the need for renal replacement therapy in patients hospitalised in intensive care units.",[62,119],"Renal Replacement Therapy for Acute Kidney Injury in ICU",[64,121,122,123],"renal resistive index","renal replacement therapy","intensive care","2025-05-27",{"date":126,"type":41},"2025-05-29",{"date":128,"type":41},"2025-01-01",{"date":130,"type":23},"2026-07-01",{"name":47,"class":48},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":142,"conditions":143,"keywords":147,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":49},"100537829","the-effect-of-mindfulness-meditation-100537829","NCT06282913","The Effect of Mindfulness Meditation","The Effect of Mindfulness Meditation Practice on Compassion Fatigue, Burnout, and Psychological Well-Being of Health Professionals Working in Oncology Units: Randomized Controlled Study","Inclusion Criteria:\n\n* Actively working in oncology clinics\n* At least 1 year of working experience in an oncology clinic\n* Not having a physical\u002Fmental\u002Fpsychological disorder that would prevent participation in the research.\n* Oncology nurses with a high school, undergraduate, associate or graduate degree in nursing\n* Physicians and nurses who volunteer to participate in the research will be included in the research sample.\n\nExclusion Criteria:\n\n* Physicians and nurses who have been diagnosed with a psychological disease in the last two years and are continuing their medical treatment • Physicians and nurses who did not agree to participate in the research",{"count":140,"type":23},64,[26],"Cancer is a disease that causes the most deaths worldwide and is challenging for patients and caregivers both physically and psychosocially. Physicians and nurses working in oncology clinics perform a demanding profession providing compassionate care and treatment to patients struggling with life-threatening diseases. The emotional cost of caring for patients diagnosed with cancer can lead to compassion fatigue, burnout, and decreased psychological well-being among healthcare professionals. For this reason, this research is planned as a randomized controlled study to examine the effect of Mindfulness meditation practice on compassion fatigue, burnout, and psychological well-being in physicians and nurses working in oncology units.",[144,145,146],"Burnout","Compassion Fatigue","Psychological Well-Being",[148,149,150,151,152,153],"Mindfulness meditation","compassion fatigue","burnout","psychological well-being","oncology units","health professionals","2025-03-12",{"date":156,"type":41},"2025-03-17",{"date":158,"type":23},"2025-05",{"date":160,"type":23},"2025-12",{"name":47,"class":48},""]